Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 14, 2020

SELL
$8.9 - $19.08 $2.79 Million - $5.99 Million
-313,922 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$11.61 - $17.21 $2.97 Million - $4.4 Million
-255,740 Reduced 44.89%
313,922 $4.51 Million
Q3 2019

Nov 13, 2019

SELL
$10.01 - $16.87 $2.1 Million - $3.54 Million
-209,994 Reduced 26.93%
569,662 $7.92 Million
Q2 2019

Aug 13, 2019

BUY
$12.51 - $17.28 $375,325 - $518,434
30,002 Added 4.0%
779,656 $11.4 Million
Q1 2019

May 14, 2019

SELL
$10.26 - $16.24 $307,820 - $487,232
-30,002 Reduced 3.85%
749,654 $11.9 Million
Q3 2018

Nov 13, 2018

BUY
$14.99 - $22.14 $11.7 Million - $17.3 Million
779,656 New
779,656 $12.6 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $736M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Foresite Capital Management Iii, LLC Portfolio

Follow Foresite Capital Management Iii, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Foresite Capital Management Iii, LLC with notifications on news.